03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
17:39 , Apr 20, 2018 |  BioCentury  |  Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
16:46 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

UCB reports interim Phase II data for rozanolixizumab in thrombocytopenia

UCB S.A. (Euronext:UCB) reported interim data from 28 patients with primary persistent or chronic immune thrombocytopenia (ITP) in a Phase II trial showing that subcutaneous rozanolixizumab (UCB7665) led to maximum mean reductions in total IgG...
04:56 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Syntimmune reports Phase Ia data for autoimmune disease candidate

Syntimmune Inc. (Waltham, Mass.) reported data from a Phase Ia trial in 31 healthy volunteers showing that single ascending doses of IgG-mediated autoimmune disease candidate IV SYNT001 were well tolerated with no serious adverse events...
17:35 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Momenta reports Phase I data for anti-FCRN mAb

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said its immune-mediated disease candidate M281 was safe and showed proof of mechanism in a Phase I trial in healthy volunteers. M281 is a human IgG1 mAb against neonatal Fc receptor...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:59 , Jan 5, 2018 |  BC Extra  |  Clinical News

Momenta gains on Phase I data for anti-FCRN mAb

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) added $2.80 (19%) to $17.55 on Friday after reporting that its immune-mediated disease candidate M281 was safe and showed proof of mechanism in a Phase I trial in healthy volunteers. M281...
22:10 , Jan 5, 2018 |  BC Week In Review  |  Company News

Roivant in-licenses HanAll's autoimmune candidate HL161

HanAll Biopharma Co. Ltd. (KOSDAQ:009420) granted Roivant Sciences GmbH (Basel, Switzerland) exclusive rights to develop and commercialize HL161 to treat pathogenic IgG-mediated autoimmune diseases. HanAll will receive $30 million up front and $20 million in...
23:22 , Dec 28, 2017 |  BC Extra  |  Company News

Roivant in-licenses HanAll's autoimmune candidate

HanAll Biopharma Co. Ltd. (KOSDAQ:009420) granted Roivant Sciences GmbH (Basel, Switzerland) exclusive rights to develop and commercialize HL161 to treat pathogenic IgG-mediated autoimmune diseases. HanAll will receive $30 million up front and $20 million in...